2026 Global: Absorbable Coronary Stent Market -Competitive Review (2032) report
Description
The 2026 Global: Absorbable Coronary Stent Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Abbott Laboratories, headquartered in Abbott Park, United States, has driven the absorbable coronary stent segment with its Absorb BVS platform. The device aimed to provide temporary vascular support and then resorb, potentially reducing long-term stent-related events. While regulatory and safety concerns reshaped its market trajectory, Abbott's R&D and commercialization network highlighted the strategic importance of bioabsorbable scaffolds in contemporary interventional cardiology. REVA Medical, based in San Diego, United States, advanced PLLA-based scaffolds that fueled early clinical exploration of resorbable coronary technology and spurred trials in Europe. Although the REVA program faced financial and regulatory setbacks, the company contributed essential performance data and design insights for subsequent generations. Biotronik, with headquarters in Berlin, Germany, entered the BRS arena through Magmaris, a magnesium-based scaffold offering an alternative degradation timeline and mechanical behavior to polymeric systems. Lifetech Scientific, Shenzhen, China, built a portfolio, including bioabsorbable options, leveraging manufacturing scale and demand for devices.
Cordis, a Cardinal Health subsidiary, has long operated its stent business from the United States, with organizational roots in Santa Clara, California, and a distribution network that supported patient access and trial enrollment in BRS programs. The company’s strategic involvement in absorbable technology has intersected with European and Asian regulatory workflows, reflecting the complexity of introducing bioresorbable scaffolds to practice. Meril Life Sciences, headquartered in Ahmedabad, India, has actively pursued bioabsorbable concepts within its growing cardiovascular portfolio, aligning product development with regional demand and clinical collaborations across Asia and the Middle East. Terumo Corporation, based in Tokyo, Japan, maintains a broad stent portfolio and has explored bioabsorbable concepts through collaborations and internal research, aiming to balance performance, safety, and manufacturability for diverse markets. Together these firms illustrate how established cardiovascular players leverage regional networks, regulatory knowledge, and manufacturing capability to advance absorbable scaffolds despite safety signals that have tempered enthusiasm.
AnGes, headquartered in Osaka, Japan, has pursued bioabsorbable coronary scaffolds within its broader vascular portfolio, engaging in partnerships to advance material science and regulatory strategies across Asia and Europe. Elixir Medical, based in Santa Clara, United States, has developed polymer-based scaffolds and next‑generation platforms, focusing on resorption kinetics and drug-elution compatibility. Biosensors International, headquartered in Singapore, maintains a portfolio that includes bioabsorbable candidates alongside conventional stents, supporting multi-regional clinical programs and regulatory submissions. The trio illustrates divergent geographic footprints, with Japan and Singapore anchoring Asia-Pacific R&D and manufacturing capabilities while the United States links to translational research and trial networks. Ongoing safety signals and evolving regulatory guidance have tempered enthusiasm, but advances in polymer chemistry, magnesium alloys, and surface engineering continue to drive exploration of resorbable scaffolds for coronary indications. Industry collaboration and clinical registries remain essential to define benefits, risks, and patient selection criteria across settings for future trials.
Abbott Laboratories, headquartered in Abbott Park, United States, has driven the absorbable coronary stent segment with its Absorb BVS platform. The device aimed to provide temporary vascular support and then resorb, potentially reducing long-term stent-related events. While regulatory and safety concerns reshaped its market trajectory, Abbott's R&D and commercialization network highlighted the strategic importance of bioabsorbable scaffolds in contemporary interventional cardiology. REVA Medical, based in San Diego, United States, advanced PLLA-based scaffolds that fueled early clinical exploration of resorbable coronary technology and spurred trials in Europe. Although the REVA program faced financial and regulatory setbacks, the company contributed essential performance data and design insights for subsequent generations. Biotronik, with headquarters in Berlin, Germany, entered the BRS arena through Magmaris, a magnesium-based scaffold offering an alternative degradation timeline and mechanical behavior to polymeric systems. Lifetech Scientific, Shenzhen, China, built a portfolio, including bioabsorbable options, leveraging manufacturing scale and demand for devices.
Cordis, a Cardinal Health subsidiary, has long operated its stent business from the United States, with organizational roots in Santa Clara, California, and a distribution network that supported patient access and trial enrollment in BRS programs. The company’s strategic involvement in absorbable technology has intersected with European and Asian regulatory workflows, reflecting the complexity of introducing bioresorbable scaffolds to practice. Meril Life Sciences, headquartered in Ahmedabad, India, has actively pursued bioabsorbable concepts within its growing cardiovascular portfolio, aligning product development with regional demand and clinical collaborations across Asia and the Middle East. Terumo Corporation, based in Tokyo, Japan, maintains a broad stent portfolio and has explored bioabsorbable concepts through collaborations and internal research, aiming to balance performance, safety, and manufacturability for diverse markets. Together these firms illustrate how established cardiovascular players leverage regional networks, regulatory knowledge, and manufacturing capability to advance absorbable scaffolds despite safety signals that have tempered enthusiasm.
AnGes, headquartered in Osaka, Japan, has pursued bioabsorbable coronary scaffolds within its broader vascular portfolio, engaging in partnerships to advance material science and regulatory strategies across Asia and Europe. Elixir Medical, based in Santa Clara, United States, has developed polymer-based scaffolds and next‑generation platforms, focusing on resorption kinetics and drug-elution compatibility. Biosensors International, headquartered in Singapore, maintains a portfolio that includes bioabsorbable candidates alongside conventional stents, supporting multi-regional clinical programs and regulatory submissions. The trio illustrates divergent geographic footprints, with Japan and Singapore anchoring Asia-Pacific R&D and manufacturing capabilities while the United States links to translational research and trial networks. Ongoing safety signals and evolving regulatory guidance have tempered enthusiasm, but advances in polymer chemistry, magnesium alloys, and surface engineering continue to drive exploration of resorbable scaffolds for coronary indications. Industry collaboration and clinical registries remain essential to define benefits, risks, and patient selection criteria across settings for future trials.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
